Form 4: Pure Bioscience Exec VP Acquires 155,000 Stock Options
SEC Form 4
Thomas Myers, Exec VP of Tech & Development at Pure Bioscience, acquired 155,000 stock options on August 20, 2024.
Summary
- On August 20, 2024, Thomas Richard Myers, the Executive VP of Tech & Development at Pure Bioscience, Inc. acquired 155,000 stock options.
- The exercise price of these options is $0.07.
- The options vest in four equal installments on November 20, 2024, February 20, 2025, May 20, 2025, and August 20, 2025.
- The expiration date for these options is August 20, 2034.
- Following the transaction, Myers directly owns 155,000 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants, which is a common practice. The vesting schedule and exercise price are standard.
Positives
- The acquisition of stock options by an executive could signal confidence in the company's future performance.
Industry Context
Executive compensation through stock options is a common practice in publicly traded companies to align management's interests with those of shareholders.
Stakeholder Impact
- The granting of stock options to executives can incentivize them to improve company performance, potentially benefiting shareholders.
Key Dates
| Date | Description |
|---|---|
| 08/20/2024 | Date of earliest transaction: acquisition of 155,000 stock options. |
| 11/20/2024 | First vesting date for the stock options. |
| 02/20/2025 | Second vesting date for the stock options. |
| 05/20/2025 | Third vesting date for the stock options. |
| 08/20/2025 | Fourth vesting date for the stock options. |
| 08/20/2034 | Expiration date of the stock options. |
| 08/22/2024 | Date of Form 4 filing. |
Keywords
stock options, executive compensation, Form 4, PURE Bioscience, Thomas Myers, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.